Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.

Prostate cancer and prostatic diseases - 1 Mar 2019

Möller Axel, Olsson Henrik, Grönberg Henrik, Eklund Martin, Aly Markus, Nordström Tobias

Abstract excerpt

BACKGROUND: Several blood-based tests have been suggested to improve prostate cancer testing. The Stockholm3 test has been shown to reduce the number of prostate biopsies, to decrease detection of low-grade cancer and to maintain the detection rate of ISUP Gleason Group (GG) ≥ 2 cancer in a screening-by-invitation setting. We aimed to validate the performance of the Stockholm3 test in an independent, clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Diagnosis, Differential

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematologic Tests

Share to Neoplasm Grading

Share to Norway

Share to Prostatic Neoplasms

Share to ROC Curve

Share to Sweden

Source

Identifiers

PMID: 30171228
DOI: 10.1038/s41391-018-0082-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.PMID 30171228Read ↗

Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.Semantic proximity Read ↗

The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.Semantic proximity Read ↗

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.Semantic proximity Read ↗

A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.Semantic proximity Read ↗

Prostate cancer risk-stratification using proteomic estimation of KLK3 improves accuracy in screening applications: a population-based cohort study in the UK BiobankSemantic proximity Read ↗

Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study.Semantic proximity Read ↗

Improved prostate cancer prediction by combining Prostate-Specific Antigen (PSA) test results with Genetic Risk Scores (GRS/PRS)Semantic proximity Read ↗

A Urine-Based Exosomal Gene Expression Test Stratifies Risk of High-Grade Prostate Cancer in Men with Prior Negative Prostate Biopsy Undergoing Repeat BiopsySemantic proximity Read ↗

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.Semantic proximity Read ↗

Genetic correction of PSA values using sequence variants associated with PSA levels.Semantic proximity Read ↗

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation CarriersSemantic proximity Read ↗

Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.